RPP SRL

Lobbying Organisation RPP SRL

Date published 10 May, 2023

Relevant Matter Legislation

Public Policy Area Health

Period 1 Jan, 2023 to 30 Apr, 2023

Specific Details Novartis: Request meeting on radiopharmaceuticals

Intended results Better understanding of complex area of clinical development. A request was made to schedule a meeting with the MEP to discuss possible areas of amendments to the Pharmaceutical Legislation.

Name of person primarily responsible for lobbying on this activity Juliana Azevedo de Sá

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? Yes

Client(s)

Client 1

Company name Novartis RLT

CRO number (if applicable)

Company address Rue de la Tour de l’Ile 4, 1204 Genève, Switzerland

Main business or activity

Company website https://www.adacap.com/

Contact email address jasminka.taleska@novartis.com

Contact phone number +41 793146205

Contact address Rue de la Tour de l’Ile 4, 1204 Genève, Switzerland

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Email (2-5)

A request was made to schedule a meeting with the MEP to discuss possible areas of amendments to the Pharmaceutical Legislation. The meeting didn't take place.

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Deirdre Clune MEP (European Parliament)